Dyno Therapeutics is at the forefront of revolutionizing gene therapy through its innovative application of artificial intelligence (AI) to develop advanced Adeno-Associated Virus (AAV) vectors. The company's proprietary CapsidMap™ platform enables the systematic optimization of AAV capsids, which are essential for effective gene delivery. By leveraging high-throughput in vivo experimental data and machine learning algorithms, Dyno is able to create novel capsids that enhance delivery efficiency, safety, and manufacturability. This technology aims to overcome the limitations of existing gene therapies, which often rely on a limited number of naturally occurring capsids that face challenges such as pre-existing immunity and payload size restrictions.

Through strategic partnerships with leading biopharmaceutical companies, including Astellas and Roche, Dyno Therapeutics is expanding the therapeutic potential of gene therapies to address a wider array of diseases, including those affecting the liver, muscle, and central nervous system. The collaboration with Astellas, for instance, focuses on developing next-generation AAV vectors specifically for skeletal and cardiac muscle applications. With significant funding and a commitment to innovation, Dyno is positioned to enhance the landscape of gene therapy, making it more accessible and effective for patients with previously untreatable conditions.

United States

Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy.Using machine learning and quantitative high-throughput in vivo experimentation, they are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

Dyno Therapeutics

Company Details